Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Hemoglobinopathies Drugs Industry: Supply and Demand, Markets and Prices 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Hemoglobinopathies Drugs Market Status and Forecast (2016-2027)
      • 1.3.2 Global Hemoglobinopathies Drugs Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Hemoglobinopathies Drugs Supply by Company

    • 2.1 Global Hemoglobinopathies Drugs Sales Volume by Company
    • 2.2 Global Hemoglobinopathies Drugs Sales Value by Company
    • 2.3 Global Hemoglobinopathies Drugs Price by Company
    • 2.4 Hemoglobinopathies Drugs Production Location and Sales Area of Main Manufacturers
    • 2.5 Trend of Concentration Rate

    3 Global and Regional Hemoglobinopathies Drugs Market Status by Category

    • 3.1 Hemoglobinopathies Drugs Category Introduction
      • 3.1.1 Thalassemia Therapy
      • 3.1.2 Sickle Cell Disease(SCD) Therapy
      • 3.1.3 Other Therapy
    • 3.2 Global Hemoglobinopathies Drugs Market by Category
      • 3.2.1 Global Hemoglobinopathies Drugs Sales Volume by Category (2016-2021)
      • 3.2.2 Global Hemoglobinopathies Drugs Sales Value by Category (2016-2021)
      • 3.2.3 Global Hemoglobinopathies Drugs Price by Category (2016-2021)
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Hemoglobinopathies Drugs Market Status by End User/Segment

    • 4.1 Hemoglobinopathies Drugs Segment by End User/Segment
      • 4.1.1 Alpha Thalassemia
      • 4.1.2 Beta thalassemia
      • 4.1.3 Sickle Cell Disease
      • 4.1.4 Hb Variants Diseases
    • 4.2 Global Hemoglobinopathies Drugs Market by End User/Segment
      • 4.2.1 Global Hemoglobinopathies Drugs Sales Volume by End User/Segment (2016-2021)
      • 4.2.2 Global Hemoglobinopathies Drugs Sales Value by End User/Segment (2016-2021)
      • 4.2.3 Global Hemoglobinopathies Drugs Price by End User/Segment (2016-2021)
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Hemoglobinopathies Drugs Market Status by Region

    • 5.1 Global Hemoglobinopathies Drugs Market by Region
      • 5.1.1 Global Hemoglobinopathies Drugs Sales Volume by Region
      • 5.1.2 Global Hemoglobinopathies Drugs Sales Value by Region
    • 5.2 North America Hemoglobinopathies Drugs Market Status
    • 5.3 Europe Hemoglobinopathies Drugs Market Status
    • 5.4 Asia Pacific Hemoglobinopathies Drugs Market Status
    • 5.5 Central & South America Hemoglobinopathies Drugs Market Status
    • 5.6 Middle East & Africa Hemoglobinopathies Drugs Market Status

    6 North America Hemoglobinopathies Drugs Market Status

    • 6.1 North America Hemoglobinopathies Drugs Market by Country
      • 6.1.1 North America Hemoglobinopathies Drugs Sales Volume by Country (2016-2021)
      • 6.1.2 North America Hemoglobinopathies Drugs Sales Value by Country (2016-2021)
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Hemoglobinopathies Drugs Market Status

    • 7.1 Europe Hemoglobinopathies Drugs Market by Country
      • 7.1.1 Europe Hemoglobinopathies Drugs Sales Volume by Country (2016-2021)
      • 7.1.2 Europe Hemoglobinopathies Drugs Sales Value by Country (2016-2021)
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Hemoglobinopathies Drugs Market Status

    • 8.1 Asia Pacific Hemoglobinopathies Drugs Market by Country
      • 8.1.1 Asia Pacific Hemoglobinopathies Drugs Sales Volume by Country (2016-2021)
      • 8.1.2 Asia Pacific Hemoglobinopathies Drugs Sales Value by Country (2016-2021)
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Hemoglobinopathies Drugs Market Status

    • 9.1 Central & South America Hemoglobinopathies Drugs Market by Country
      • 9.1.1 Central & South America Hemoglobinopathies Drugs Sales Volume by Country (2016-2021)
      • 9.1.2 Central & South America Hemoglobinopathies Drugs Sales Value by Country (2016-2021)
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Hemoglobinopathies Drugs Market Status

    • 10.1 Middle East & Africa Hemoglobinopathies Drugs Market by Country
      • 10.1.1 Middle East & Africa Hemoglobinopathies Drugs Sales Volume by Country (2016-2021)
      • 10.1.2 Middle East & Africa Hemoglobinopathies Drugs Sales Value by Country (2016-2021)
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Supply Chain and Manufacturing Cost Analysis

    • 11.1 Supply Chain Analysis
    • 11.2 Production Process Chart Analysis
    • 11.3 Raw Materials and Key Suppliers Analysis
      • 11.3.1 Raw Materials Introduction
      • 11.3.2 Raw Materials Key Suppliers List
    • 11.4 Hemoglobinopathies Drugs Manufacturing Cost Analysis
    • 11.5 Hemoglobinopathies Drugs Sales Channel and Distributors Analysis
      • 11.5.1 Hemoglobinopathies Drugs Sales Channel
      • 11.5.2 Hemoglobinopathies Drugs Distributors
    • 11.6 Hemoglobinopathies Drugs Downstream Major Buyers

    12 Global Hemoglobinopathies Drugs Market Forecast by Category and by End User/Segment

    • 12.1 Global Hemoglobinopathies Drugs Sales Volume and Sales Value Forecast (2022-2027)
    • 12.2 Global Hemoglobinopathies Drugs Forecast by Category
      • 12.2.1 Global Hemoglobinopathies Drugs Sales Volume Forecast by Category
      • 12.2.2 Global Hemoglobinopathies Drugs Sales Value Forecast by Category
      • 12.2.3 Global Hemoglobinopathies Drugs Price Forecast by Category
    • 12.3 Global Hemoglobinopathies Drugs Forecast by End User/Segment
      • 12.3.1 Global Hemoglobinopathies Drugs Sales Volume Forecast by End User/Segment
      • 12.3.2 Global Hemoglobinopathies Drugs Sales Value Forecast by End User/Segment
      • 12.3.3 Global Hemoglobinopathies Drugs Price Forecast by End User/Segment

    13 Global Hemoglobinopathies Drugs Market Forecast by Region/Country

    • 13.1 Global Hemoglobinopathies Drugs Market Forecast by Region (2022-2027)
      • 13.1.1 Global Hemoglobinopathies Drugs Sales Volume Forecast by Region (2022-2027)
      • 13.1.2 Global Hemoglobinopathies Drugs Sales Value Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Sangamo BioSciences Inc.
      • 14.1.1 Company Information
      • 14.1.2 Hemoglobinopathies Drugs Product Introduction
      • 14.1.3 Sangamo BioSciences Inc. Hemoglobinopathies Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Prolong Pharmaceuticals
      • 14.2.1 Company Information
      • 14.2.2 Hemoglobinopathies Drugs Product Introduction
      • 14.2.3 Prolong Pharmaceuticals Hemoglobinopathies Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Pfizer Inc.
      • 14.3.1 Company Information
      • 14.3.2 Hemoglobinopathies Drugs Product Introduction
      • 14.3.3 Pfizer Inc. Hemoglobinopathies Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Mast Therapeutics
      • 14.4.1 Company Information
      • 14.4.2 Hemoglobinopathies Drugs Product Introduction
      • 14.4.3 Mast Therapeutics Hemoglobinopathies Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 HemaQuest Pharmaceuticals
      • 14.5.1 Company Information
      • 14.5.2 Hemoglobinopathies Drugs Product Introduction
      • 14.5.3 HemaQuest Pharmaceuticals Hemoglobinopathies Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Global Blood Therapeutics Inc.
      • 14.6.1 Company Information
      • 14.6.2 Hemoglobinopathies Drugs Product Introduction
      • 14.6.3 Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 Genetix Pharmaceuticals/Bluebird Bio
      • 14.7.1 Company Information
      • 14.7.2 Hemoglobinopathies Drugs Product Introduction
      • 14.7.3 Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 Gamida Cell
      • 14.8.1 Company Information
      • 14.8.2 Hemoglobinopathies Drugs Product Introduction
      • 14.8.3 Gamida Cell Hemoglobinopathies Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 Emmaus Life Sciences, Inc.
      • 14.9.1 Company Information
      • 14.9.2 Hemoglobinopathies Drugs Product Introduction
      • 14.9.3 Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.9.4 SWOT Analysis
    • 14.10 Celgene Corporation
      • 14.10.1 Company Information
      • 14.10.2 Hemoglobinopathies Drugs Product Introduction
      • 14.10.3 Celgene Corporation Hemoglobinopathies Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.10.4 SWOT Analysis
    • 14.11 Biogen Idec
    • 14.12 Alnylam Pharmaceuticals

    15 Conclusion

      16 Methodology

      Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Hemoglobinopathies Drugs market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Hemoglobinopathies Drugs market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

      Segmented by Category
      Thalassemia Therapy
      Sickle Cell Disease(SCD) Therapy
      Other Therapy

      Segmented by End User/Segment
      Alpha Thalassemia
      Beta thalassemia
      Sickle Cell Disease
      Hb Variants Diseases

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      Sangamo BioSciences Inc.
      Prolong Pharmaceuticals
      Pfizer Inc.
      Mast Therapeutics
      HemaQuest Pharmaceuticals
      Global Blood Therapeutics Inc.
      Genetix Pharmaceuticals/Bluebird Bio
      Gamida Cell
      Emmaus Life Sciences, Inc.
      Celgene Corporation
      Biogen Idec
      Alnylam Pharmaceuticals
      Buy now